Literature DB >> 10879076

[A senile case of acute necrotizing myopathy presenting prolonged severe muscle paralysis due to high dose glucocorticoid and muscle relaxant].

T Sato1, K Takahashi, Y Okuma, Y Mizuno, K Noto, M Katae, T Dambara, Y Fukuchi.   

Abstract

An 82-year old man was admitted with dyspnea, productive cough and wheezing. In addition to antibiotics (meropenem trihydrate 0.5 g/day), glucocorticoids (hydrocortisone 1.250 mg, methylpredonisolone 4.250 mg) were administered for the severe bronchospasms. Since his respiratory condition deteriorated, he underwent mechanical ventilation using a muscle relaxant (vecuronium bromide, total dose 776 mg) in combination with high dose glucocorticoid. As his pneumonia improved on the 10th hospital day, we started weaning him from the ventilator. However, we were unable to complete weaning from the ventilator because of prolonged quadriplegia and paralysis of the respiratory muscles. A few days later, myoglobinuria appeared. Electrophysiological examinations suggested the involvement of both neuromuscular junctions and muscles. Muscle biopsy showed rhabdomyolysis. Acute necrotizing myopathy was diagnosed due to high doses of glucocorticoid, muscle relaxant, or both. He required about 3 months to be weaned from the mechanical ventilation, and another 3 months to leave the hospital. Based on our experience, we should consider acute myopathy as an adverse effect of glucocorticoids, muscle relaxants or both in elderly patients who require mechanical ventilation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10879076     DOI: 10.3143/geriatrics.37.250

Source DB:  PubMed          Journal:  Nihon Ronen Igakkai Zasshi        ISSN: 0300-9173


  1 in total

1.  A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin.

Authors:  Fabrice Petitjeans; Julien Nadaud; Jean Paul Perez; Bruno Debien; Frederic Olive; Thierry Villevieille; Bruno Pats
Journal:  Eur J Clin Pharmacol       Date:  2003-10-24       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.